Eurofins Genomics U.S., together with its subsidiary BlueHeron Biotechnology, has launched a series of SARS-CoV-2 plasmid DNA controls that can be used to detect the presence of the SARS-CoV-2 virus. They are intended to be used for R&D and IVD diagnostic applications. Eurofins Genomics U.S. offers three different COVID-19 controls targeting key segments of the 30,000 base SARS-CoV-2 genome. One of the positive controls, CVGP, covers a wide swath of the sequence so that users can set up m...